



## IDT Biologika and SK bioscience Partner on Development and Manufacturing of Drug Product for MSD's Zaire Ebola Vaccine with an Updated Manufacturing Process

Dessau-Rosslau (Germany), March 23, 2026 – IDT Biologika, a leading CDMO providing end-to-end services in the development and manufacturing of viral vaccines, gene and immune therapeutics and aseptic fill-finish of sterile injectables, announced that, and SK bioscience, an innovative vaccine and biotech company, committed to vaccine development and manufacturing, announced that they have signed a contract for the contract development and manufacturing of the drug product for the Zaire Ebola vaccine with an updated manufacturing process, being developed in collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA) and Hilleman Laboratories.

The agreement forms part of a development project supported by approximately USD 30 million in funding from CEPI, the Coalition for Epidemic Preparedness Innovations. The project focuses on addressing the manufacturing complexity and ultra-cold chain requirements associated with MSD's existing Zaire Ebola vaccine. Key objectives are to enhance supply stability and accessibility by increasing manufacturing yield and improving thermo stability.

Under the agreement, SK bioscience will produce drug substance, while IDT Biologika will leverage its CDMO expertise, know-how, and advanced facilities to undertake drug product development and manufacturing.

This collaboration reflects the broader integration strategy that has been progressively strengthened since SK bioscience acquired IDT Biologika. The Germany-based company continues to expand its role beyond that of a traditional CDMO, evolving into a key hub within SK bioscience's global development and manufacturing network.

Jinseon Park, COO of SK bioscience, said, "Through this agreement, the combined development and manufacturing capabilities of SK bioscience and IDT will enhance the execution of global infectious disease response projects. We will continue to advance our integrated manufacturing platform to strengthen our ability to respond reliably to international public health needs."

Dr. Sally Choe, CEO of IDT Biologika, added, "This collaboration reflects our strong partnership with SK bioscience and our shared ambition to build an integrated global manufacturing network."

2,352 characters (including spaces)



Picture



#### About SK bioscience

[SK bioscience](#) is an innovative vaccine and biotech company, committed to vaccine development and manufacturing to enable more equitable access to vaccines around the world. Leveraging strengths on cutting-edge technologies, SK bioscience has been dedicated to promoting human health from prevention to cure across the globe. With the cooperation of domestic and international governments, regulatory agencies, healthcare providers, doctors, and medical experts, all of the SK colleagues are passionately committed to providing high-quality vaccines to those who need them and better public healthcare solutions.

#### About IDT Biologika

With passion we bring pharmaceutical solutions to life.

[IDT Biologika](#), part of SK bioscience, is a leading CDMO specializing in end-to-end development and manufacturing of viral vaccines, gene and immune therapeutics, and aseptic fill-finish of sterile injectables. With more than 100 years of biopharmaceutical expertise, the company combines proven know-how with advanced platform technologies to support our customers' projects.

The integrated services span the entire product lifecycle – from process development and drug substance manufacturing (cell culture and microbial systems) to clinical and commercial fill-finish, complemented by quality control, analytical testing, and packaging. IDT Biologika supports the successful market launch of protein- and antibody-based biologics and biosimilars, including vaccines, gene and immune therapeutics, oncolytic viruses, and other sterile injectables that help prevent and treat diseases worldwide.

Corporate Communications:

Corinna Meisel | M +49 (0)173 9249671 | [corinna.meisel@idt-biologika.de](mailto:corinna.meisel@idt-biologika.de)  
[www.idt-biologika.com](http://www.idt-biologika.com)